Back to Search
Start Over
Effect of Nocturnal Oxygen on Blood Pressure Response to Altitude Exposure in COPD - Data from a Randomized Placebo-Controlled Cross-Over Trial.
- Source :
-
International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2021 Dec 24; Vol. 16, pp. 3503-3512. Date of Electronic Publication: 2021 Dec 24 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Purpose: Patients with chronic obstructive pulmonary disease (COPD) are particularly vulnerable to hypoxia-induced autonomic dysregulation. Hypoxemia is marked during sleep. In COPD, altitude exposure is associated with an increase in blood pressure (BP) and a decrease in baroreflex-sensitivity (BRS). Whether nocturnal oxygen therapy (NOT) may mitigate these cardiovascular autonomic changes in COPD at altitude is unknown.<br />Materials and Methods: In a randomized placebo-controlled cross-over trial, 32 patients with moderate-to-severe COPD living <800 m were subsequently allocated to NOT and placebo during acute exposure to altitude. Measurements were done at low altitude at 490 m and during two stays at 2048 m on NOT (3 L/min) and placebo (3 L/min, ambient air) via nasal cannula. Allocation and intervention sequences were randomized. Outcomes of interest were BP, BRS (from beat-to-beat BP measurement), BP variability (BPV), and heart rate.<br />Results: About 23/32 patients finished the trial per protocol (mean (SD) age 66 (5) y, FEV <subscript>1</subscript> 62 (14) % predicted) and 9/32 experienced altitude-related illnesses (8 vs 1, p < 0.05 placebo vs NOT). NOT significantly mitigated the altitude-induced increase in systolic BP compared to placebo (Δ median -5.8 [95% CI -22.2 to -1.4] mmHg, p = 0.05) but not diastolic BP (-3.5 [95% CI -12.6 to 3.0] mmHg; p = 0.21) or BPV. BRS at altitude was significantly higher in NOT than in placebo (1.7 [95% CI 0.3 to 3.4] ms/mmHg, p = 0.02).<br />Conclusion: NOT may protect from hypoxia-induced autonomic dysregulation upon altitude exposure in COPD and thus protect from a relevant increase in BP and decrease in BRS. NOT may provide cardiovascular benefits in COPD during conditions of increased hypoxemia and may be considered in COPD travelling to altitude.<br />Competing Interests: Prof. Dr. Silvia Ulrich reports grants from Swiss National Science Foundation, Swiss Lung League, Zurich Lung; grants, personal fees from Janssen/Actelion SA, Orpha Swiss; and personal fees from MSD SA, Switzerland, outside the submitted work. The authors declare that they do not have any financial or other conflict of interest to declare in relation with this work.<br /> (© 2021 Meszaros et al.)
Details
- Language :
- English
- ISSN :
- 1178-2005
- Volume :
- 16
- Database :
- MEDLINE
- Journal :
- International journal of chronic obstructive pulmonary disease
- Publication Type :
- Academic Journal
- Accession number :
- 34992358
- Full Text :
- https://doi.org/10.2147/COPD.S331658